The Effect of Neoadjuvant Chemotherapy on Hormone Receptor Status,HER2/neu and Prolactin in Breast Cancer

Ferlay J. , Shin H.R. , Bray F. , Forman D. , Mathers C. , Parkin D.M. : Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893–2917, 2010.

Chatenoud L. , Bertuccio P. , Bosetti C. , Levi F. , Curado M.P. , Malvezzi M. , Negri E. , Vecchia C.L. : Trends in cancer mortality in Brazil, 1980–2004. Eur J Cancer Prev, 19: 79–86, 2010.

Karihtala P. , Winqvist R. , Bloigu R. , Jukkola-Vuorinen A. : Long-term observational follow-up study of breast cancer diagnosed in women </=40 years old. Breast, 19: 456–461, 2010.

Cianfrocca M. , Goldstein L.J. : Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9: 606–616, 2004.

Campbell H.E. , Gray A.M. , Harris A.L. , Briggs A.H. , Taylor M.A. : Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer, 103: 776–786, 2010.

Saurel C.A. , Patel T.A. , Perez E.A. : Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer, 10: 196–208, 2010.

Kaufmann M. , von Minckwitz G. , Bear H.D. , Buzdar A. , Mc-Gale P. , Bonnefoi H. , Colleoni M. , Denkert C. , Eiermann W. , Jackesz R. , Makris A. , Miller W. , Pierga J.Y. , Semiglazov V. , Schneeweiss A. , Souchon R. , Stearns V. , Untch M. , Loibl S. : Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 18: 1927–1934, 2007.

Finek J. , Holubec L.J. , Topolcan O. , Elgrova L. , Skalova A. , Pecen L. : The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res, 27: 1893–1896, 2007.

Duffy M.J. : Predictive markers in breast and other cancers: a review. Clin Chem, 51: 494–503, 2005.

Prisack H.B. , Karreman C. , Modlich O. , Audretsch W. , Danae M. , Rezai M. , Bojar H. : Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy. Anticancer Res, 25: 4615–4621, 2005.

Burcombe R.J. , Makris A. , Richman P.I. , Daley F.M. , Noble S. , Pittam M. , Wright D. , Allen S.A. , Dove J. , Wilson G.D. : Evaluation of ER, Pg R, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer, 92: 147–155, 2005.

Clevenger C.V. : Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis, 18: 75–86, 2003.

Vaclavicek A. , Hemminki K. , Bartram C.R. , Wagner K. , Wappenschmidt B. , Meindl A. , Schmutzler R.K. , Klaes R. , Untch M. , Burwinkel B. , Forsti A. : Association of prolactin and its receptor gene regions with familial breast cancer. J Clin Endocrinol Metab, 91: 1513–1519, 2006.

De Placido S. , De Laurentiis M. , Carlomagno C. , Gallo C. , Perrone F. , Pepe S. , Ruggiero A. , Marinelli A. , Pagliarulo C. , Panico L. , Pettinato G. , Petrella G. , Bianco A.R. : Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res, 9: 1039–1046, 2003.

LaPensee E.W. , Schwemberger S.J. , LaPensee C.R. , Bahassi el M. , Afton S.E. , Ben-Jonathan N. : Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis, 30: 1298–1304, 2009.

Burge C.N. , Chang H.R. , Apple S.K. : Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast, 15: 167–172, 2006.

Burcombe R. , Wilson G.D. , Dowsett M. , Khan I. , Richman P.I. , Daley F. , Detre S. , Makris A. : Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res, 8: R31, 2006.

Lee S.H. , Chung M.A. , Quddus M.R. , Steinhoff M.M. , Cady B. : The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg, 186: 348–350, 2003.

Arens N. , Bleyl U. , Hildenbrand R. : HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch, 446: 489–496, 2005.

Kasami M. , Uematsu T. , Honda M. , Yabuzaki T. , Sanuki J. , Uchida Y. , Sugimura H. : Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast, 17: 523–527, 2008.

Eisenhauer E.A. , Therasse P. , Bogaerts J. , Schwartz L.H. , Sargent D. , Ford R. , Dancey J. , Arbuck S. , Gwyther S. , Mooney M. , Rubinstein L. , Shankar L. , Dodd L. , Kaplan R. , Lacombe D. , Verweij J. : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45: 228–247, 2009.

Therasse P. , Arbuck S.G. , Eisenhauer E.A. , Wanders J. , Kaplan R.S. , Rubinstein L. , Verweij J. , Van Glabbeke M. , van Oosterom A.T. , Christian M.C. , Gwyther S.G. : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205–216, 2000.

Schorr M.C. , Pedrini J.L. , Savaris R.F. , Zettler C.G. : Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same? Appl Immunohistochem Mol Morphol, 18: 51–54, 2010.

Hammond M.E. , Hayes D.F. , Dowsett M. , Allred D.C. , Hagerty K.L. , Badve S. , Fitzgibbons P.L. , Francis G. , Goldstein N.S. , Hayes M. , Hicks D.G. , Lester S. , Love R. , Mangu P.B. , McShane L. , Miller K. , Osborne C.K. , Paik S. , Perlmutter J. , Rhodes A. , Sasano H. , Schwartz J.N. , Sweep F.C. , Taube S. , Torlakovic E.E. , Valenstein P. , Viale G. , Visscher D. , Wheeler T. , Williams R.B. , Wittliff J.L. , Wolff A.C. : American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28: 2784–2795, 2010.

Wolff A.C. , Hammond M.E. , Schwartz J.N. , Hagerty K.L. , Allred D.C. , Cote R.J. , Dowsett M. , Fitzgibbons P.L. , Hanna W.M. , Langer A. , McShane L.M. , Paik S. , Pegram M.D. , Perez E.A. , Press M.F. , Rhodes A. , Sturgeon C. , Taube S.E. , Tubbs R. , Vance G.H. , van de Vijver M. , Wheeler T.M. , Hayes D.F. : American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25: 118–145, 2007.

Bhatavdekar J.M. , Patel D.D. , Shah N.G. , Vora H.H. , Suthar T.P. , Ghosh N. , Chikhlikar P.R. , Trivedi T.I. : Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol, 26: 540–547, 2000.

Hirata T. , Shimizu C. , Yonemori K. , Hirakawa A. , Kouno T. , Tamura K. , Ando M. , Katsumata N. , Fujiwara Y. : Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer, 101: 1529–1536, 2009.

Taucher S. , Rudas M. , Gnant M. , Thomanek K. , Dubsky P. , Roka S. , Bachleitner T. , Kandioler D. , Wenzel C. , Steger G. , Mittlbock M. , Jakesz R. : Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer, 10: 91–98, 2003.

Precht L.M. , Lowe K.A. , Atwood M. , Beatty J.D. : Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J, 16: 362–368, 2010.

Jekel J.F. , Elmore J.G. , Katz D.L. : In: Epidemiology, Biostatistics and Preventive Medicine, Jekel J.F. , Elmore J.G. , Katz D.L. (Eds), p 139, W.B. Saunders, Philadelphia, 1996.

Yang X.R. , Chang-Claude J. , Goode E.L. , Couch F.J. , Nevanlinna H. , Milne R.L. , Gaudet M. , Schmidt M.K. , Broeks A. , Cox A. , Fasching P.A. , Hein R. , Spurdle A.B. , Blows F. , Driver K. , Flesch-Janys D. , Heinz J. , Sinn P. , Vrieling A. , Heikkinen T. , Aittomaki K. , Heikkila P. , Blomqvist C. , Lissowska J. , Peplonska B. , Chanock S. , Figueroa J. , Brinton L. , Hall P. , Czene K. , Humphreys K. , Darabi H. , Liu J. , Van ‘t Veer L.J. , van Leeuwen F.E. , Andrulis I.L. , Glendon G. , Knight J.A. , Mulligan A.M. , O'Malley F.P. , Weerasooriya N. , John E.M. , Beckmann M.W. , Hartmann A. , Weihbrecht S.B. , Wachter D.L. , Jud S.M. , Loehberg C.R. , Baglietto L. , English D.R. , Giles G.G. , McLean C.A. , Severi G. , Lambrechts D. , Vandorpe T. , Weltens C. , Paridaens R. , Smeets A. , Neven P. , Wildiers H. , Wang X. , Olson J.E. , Cafourek V. , Fredericksen Z. , Kosel M. , Vachon C. , Cramp H.E. , Connley D. , Cross S.S. , Balasubramanian S.P. , Reed M.W. , Dork T. , Bremer M. , Meyer A. , Karstens J.H. , Ay A. , Park-Simon T.W. , Hillemanns P. , Arias Perez J.I. , Rodriguez P.M. , Zamora P. , Benitez J. , Ko Y.D. , Fischer H.P. , Hamann U. , Pesch B. , Bruning T. , Justenhoven C. , Brauch H. , Eccles D.M. , Tapper W.J. , Gerty S.M. , Sawyer E.J. , Tomlinson I.P. , Jones A. , Kerin M. , Miller N. , McInerney N. , Anton-Culver H. , Ziogas A. , Shen C.Y. , Hsiung C.N. , Wu P.E. , Yang S.L. , Yu J.C. , Chen S.T. , Hsu G.C. , Haiman C.A. , Henderson B.E. , Le Marchand L. , Kolonel L.N. , Lindblom A. , Margolin S. , Jakubowska A. , Lubinski J. , Huzarski T. , Byrski T. , Gorski B. , Gronwald J. , Hooning M.J. , Hollestelle A. , van den Ouweland A.M. , Jager A. , Kriege M. , Tilanus-Linthorst M.M. , Collee M. , Wang-Gohrke S. , Pylkas K. , Jukkola-Vuorinen A. , Mononen K. , Grip M. , Hirvikoski P. , Winqvist R. , Mannermaa A. , Kosma V.M. , Kauppinen J. , Kataja V. , Auvinen P. , Soini Y. , Sironen R. , Bojesen S.E. , Dynnes Orsted D. , Kaur-Knudsen D. , Flyger H. , Nordestgaard B.G. , Holland H. , Chenevix-Trench G. , Manoukian S. , Barile M. , Radice P. , Hankinson S.E. , Hunter D.J. , Tamimi R. , Sangrajrang S. , Brennan P. , McKay J. , Odefrey F. , Gaborieau V. , Devilee P. , Huijts P.E. , Tollenaar R. , Seynaeve C. , Dite G.S. , Apicella C. , Hopper J.L. , Hammet F. , Tsimiklis H. , Smith L.D. , Southey M.C. , Humphreys M.K. , Easton D. , Pharoah P. , Sherman M.E. , Garcia-Closas M. : Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst, 103: 250–263, 2011.

Conroy S.M. , Pagano I. , Kolonel L.N. , Maskarinec G. : Mammographic density and hormone receptor expression in breast cancer: The Multiethnic Cohort Study. Cancer Epidemiol, 35: 448–452, 2011.

Baxevanis C.N. , Sotiropoulou P.A. , Sotiriadou N.N. , Papamichail M. : Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother, 53: 166–175, 2004.

Slamon D.J. , Clark G.M. , Wong S.G. , Levin W.J. , Ullrich A. , McGuire W.L. : Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177–182, 1987.

Charpin C. , Secq V. , Giusiano S. , Carpentier S. , Andrac L. , Lavaut M.N. , Allasia C. , Bonnier P. , Garcia S. : A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer, 124: 2124–2134, 2009.

Piper G.L. , Patel N.A. , Patel J.A. , Malay M.B. , Julian T.B. : Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Am Surg, 70: 1103–1106, 2004.

Janssen T. , Darro F. , Petein M. , Raviv G. , Pasteels J.L. , Kiss R. , Schulman C.C. : In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCa P, DU145, and PC3 models of the human prostate. Cancer, 77: 144–149, 1996.

Goffin V. , Bernichtein S. , Touraine P. , Kelly P.A. : Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev, 26: 400–422, 2005.

Vonderhaar B.K. : Prolactin involvement in breast cancer. Endocr Relat Cancer, 6: 389–404, 1999.

Tworoger S.S. , Hankinson S.E. : Prolactin and breast cancer risk. Cancer Lett, 243: 160–169, 2006.

Gutzman J.H. , Miller K.K. , Schuler L.A. : Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol, 88: 69–77, 2004.